Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Abdominal Wall Vascularized Composite Allotransplantation: A Scoping Review
Bustos, Valeria P. , Escandón, Joseph M. , Santamaría, Eric , Ciudad, Pedro , Forte, Antonio J. , Leckenby, Jonathan I. , Langstein, Howard N. , Manrique, Oscar J. , Forte, Antonio Jorge , Escandón, Joseph M

Mayo Clinic

Journal of Reconstructive Microsurgery | December 15, 2021 | Volume: 38 | Issue: 06 | Pages: 481-490

10.1055/s-0041-1740121 | PMID 34905782 Get It

AbstractBackground Abdominal wall vascularized composite allotransplantation (AW-VCA) is a novel reconstructive technique used for large abdominal wall defects in combination with intestinal transplantation (ITx) or multivisceral abdominal transplantation (MVTx). Since the introduction of this procedure, several studies have been published reporting their experience. This study aims to present a scoping review looking at all available evidence-based medicine information to understand the most current surgical techniques and clinical outcomes.Methods This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) extension for scoping reviews checklist. A comprehensive research strategy of several databases was conducted.Results A total of 31 studies were included in this review, which comprised animal, cadaveric, and human studies. In human studies, four surgical techniques with high flap survival rates and low complication rates were found. In cadaveric studies, it was shown that the use of iliofemoral cuff-based flaps provided adequate tissue perfusion to the abdominal wall graft. Also, the use of thoracolumbar nerves have been described to provide functionality to the AW-VCA and prevent long-term muscle atrophy.Conclusion AW-VCA is a safe and efficient alternative for patients with large and complex abdominal wall defects. The future holds a promising evolution of a functional AW-VCA, though surgeons must face and overcome the challenge of distorted anatomy frequently present in this population. Forthcoming studies with a better level of evidence are required to evaluate functionality and differences between surgical techniques.
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, Apar Kishor , Bassetti, M. , Blakely, Collin M. , Chiang, Anne C. , D’Amico, Thomas A., D’Avella, Christopher , Dowlati, Afshin , Downey, Robert J. , Florsheim, Charles, Grecula, J.C., Hann, Christine L. , Iams, Wade T. , Iyengar, Puneeth , Khalil, Maya, Koczywas, Marianna , Merritt, Robert E. , Mohindra, Nisha , Molina, Julian R. , Moran, César A. , Qin, Angel , Rusthoven, Chad G. , Santana-Dávila, Rafael , Shafique, Michael , Gregory, Kristina M., Hughes, Miranda, Molina, Julian, Ganti, Apar K , Loo, Billy W. , Edelman, Martin J. , Gold, Kathryn Ann , Goldman, Jonathan W. , Kelly, Karen , Pokharel, Saraswati , Puri, Sonam , Sands, Jacob , Waqar, Saiama N

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 13, 2021 | Volume: 19 | Issue: 12 | Pages: 1441-1464

10.6004/jnccn.2021.0058 | PMID 34902832 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
Martin, Ting , Savjani, Ricky R. , Pollom, Erqi L., Karnes, R. Jeffrey , Wong, J.K. , Motterle, Giovanni , Tosoian, Jeffrey J. , Klein, Eric A. , Stish, Bradley J. , Dess, Robert T. , Spratt, Daniel E. , Pilar, Avinash , Levin-Epstein, Rebecca , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Huland, Hartwig , Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Schwen, Zeyad , Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Chong, Natalie, Kupelian, Patrick A. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Czernin, Johannes, Gafita, Andrei , Romero, Tahmineh , Calais, Jérémie , Kishan, Amar U. , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Klein, Eric A , Ma, Ting Martin , Calais, Jeremie , Xiang, Michael H. , Grogan, Tristan , Trock, Bruce J , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Alam, Ridwan , Song, Daniel Y. , Boutros, Paul C. , Rettig, Matthew B. , Zaorsky, Nicholas G. , Berlin, Alejandro , Tward, Jonathan D. , Tilki, Derya

Mayo Clinic

JAMA Network Open | December 13, 2021 | Volume: 4 | Issue: 12 | Pages: e2138550

10.1001/jamanetworkopen.2021.38550 | PMID 34902034 Get It

Minimum standards for inpatient long‐term video‐electroencephalographic monitoring: A clinical practice guideline of the International League Against Epilepsy and International Federation of Clinical Neurophysiology
Tatum, William O. , Mani, Jayanti , Halford, Jonathan J. , Gloss, David , Fahoum, Firas , Maillard, Louis , Mothersill, Ian, Halford, Jonathan J , Fahoum, Firas , Beniczky, Sándor , Jin, Kazutaka

Mayo Clinic

Epilepsia | December 13, 2021 | Volume: 63 | Issue: 2 | Pages: 290-315

10.1111/epi.16977 | PMID 34897662 Get It

Summary The objective of this clinical practice guideline is to provide recommendations on the indications and minimum standards for inpatient long‐term video‐electroencephalographic monitoring (LTVEM). The Working Group of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology develop guidelines aligned with the Epilepsy Guidelines Task Force. We reviewed published evidence using the PRISMA (Preferred Reporting Items for Systematic Review and Meta‐Analysis) statement. We found limited high‐level evidence aimed at specific aspects of diagnosis for LTVEM performed to evaluate patients with seizures and nonepileptic events. For classification of evidence, we used the Clinical Practice Guideline Process Manual of the American Academy of Neurology. We formulated recommendations for the indications, technical requirements, and essential practice elements of LTVEM to derive minimum standards used in the evaluation of patients with suspected epilepsy using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Further research is needed to obtain evidence about long‐term outcome effects of LTVEM and to establish its clinical utility.
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
Cudkowicz, Merit , Lindborg, Stacy , Goyal, Namita , Miller, Robert G. , Burford, Matthew, Nicholson, Katharine, Mozaffar, Tahseen , Katz, Jonathan, Jenkins, Liberty, Baloh, Robert H. , Lewis, Richard A. , Staff, N., Owegi, Margaret, Berry, Donald A. , Gothelf, Yaël, Levy, Yossef S., Aricha, Revital , Kern, R. , Windebank, Anthony J. , Brown, Robert H. , Staff, Nathan P. , Cudkowicz, Merit E , Lindborg, Stacy R , Mozaffar, Tahseen , Lewis, Richard A , Brown, Robert H , Staff, Nathan P , Berry, James D.

Mayo Clinic

Muscle & Nerve | December 10, 2021 | Volume: 65 | Issue: 3 | Pages: 291-302

10.1002/mus.27472 | PMID 34890069 Get It

Abstract Introduction/Aims Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC‐NTF), a novel autologous cell‐therapy capable of targeting multiple pathways, could safely slow ALS disease progression. Methods This randomized, double‐blind, placebo‐controlled study enrolled ALS participants meeting revised El Escorial criteria, revised ALS Functional Rating Scale (ALSFRS‐R) ≥25 (screening) and ≥3 ALSFRS‐R points decline prior to randomization. Participants received three treatments of MSC‐NTF or placebo intrathecally. The primary endpoint evaluated efficacy of MSC‐NTF through a responder analysis and safety. A change in disease progression post‐treatment of ≥1.25 points/mo defines a clinical response. A pre‐specified analysis leveraged baseline ALSFRS‐R of 35 as a subgroup threshold. Results Overall, MSC‐NTF treatment was well tolerated; there were no safety concerns. Thirty‐three percent of MSC‐NTF and 28% of placebo participants met clinical response criteria at 28 wk (odds ratio [OR] = 1.33, P = .45); thus, the primary endpoint was not met. A pre‐specified analysis of participants with baseline ALSFRS‐R ≥ 35 (n = 58) showed a clinical response rate at 28 wk of 35% MSC‐NTF and 16% placebo (OR = 2.6, P = .29). Significant improvements in cerebrospinal biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support were observed with MSC‐NTF, with placebo unchanged. Discussion The study did not reach statistical significance on the primary endpoint. However, a pre‐specified subgroup suggests that MSC‐NTF participants with less severe disease may have retained more function compared to placebo. Given the unmet patient need, the results of this trial warrant further investigation.
Outcomes of Sentinel Lymph Node Biopsy for Primary Cutaneous Squamous Cell Carcinoma of the Head and Neck
Pride, Renee L. D., Lopez, Jonathan J., Brewer, Jerry D., Price, Daniel L., Otley, Clark C., Roenigk, Randall K., Arpey, Christopher J., Baum, Christian L., Pride, Renee L. D., Lopez, Jonathan J., Brewer, Jerry D., Price, Daniel L., Otley, Clark C., Roenigk, Randall K., Arpey, Christopher J., Baum, Christian L.

Mayo Clinic

Dermatologic Surgery | December 10, 2021 | Volume: 48 | Issue: 2 | Pages: 157-161

10.1097/dss.0000000000003304 | PMID 34889209 Get It

BACKGROUND Limited data exist on sentinel lymph node biopsy (SLNB) for cutaneous squamous cell carcinoma (cSCC) of the head and neck. OBJECTIVE To review the results of SLNB for patients with cSCC of the head and neck at the authors’ institution. MATERIALS AND METHODS A retrospective review was completed for patients who underwent SLNB for cSCC of the head and neck over 19 years. Patient demographics, immune status, tumor stage, total patients with positive SLNB, local recurrence, nodal recurrence, in-transit metastasis, and disease-specific death were recorded. RESULTS Sixty patients underwent lymphoscintigraphy, and an SLN was identified in 58 patients. The mean follow-up was 3.2 years (range, 15 days–16 years). Four patients (6.9%) had a positive SLNB. All were Brigham and Women's Hospital (BWH) stage T2b tumors. Three of these patients were immunosuppressed, 3 patients underwent neck dissection, and 2 patients received adjuvant radiation. None developed local or regional recurrence. Of the 53 patients with a negative SLNB, there were 4 local recurrences, 2 in-transit metastases, and no nodal recurrences. CONCLUSION Immunosuppressed patients with tumors BWH stage T2b or greater may be a reasonable cohort to focus future prospective studies on the utility of SLNB in cSCC of the head and neck.
Abstract 112: Use of Evidence-Based Therapies in the Treatment of Cardiovascular Comorbidities and Risk Factors in Patients with Atrial Fibrillation: Findings From the ORBIT-AF Registry
Hess, Paul L. , Kim, Sunghee , Piccini, Jonathan P. , Chang, Paul, Ansell, Jack , Go, Alan S. , Allen, Larry A. , Gersh, Bernard J. , Hylek, Elaine M. , Mahaffey, Kenneth W. , Freeman, James V. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 8, 2021 | Volume: 5 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.5.suppl_1.a112 Get It

Background: The use of evidence-based therapies to treat cardiovascular comorbidities and risk factors in patients with AF in outpatient clinical practice has not been well characterized. Methods: Using a large, community-based registry of patients with AF in the United States, the prevalence of cardiovascular comorbidities and corresponding use of evidence-based therapies were determined. Results: Among 9,589 enrolled patients with AF, the median age was 75 years; 57.8% were male; 10.7% were non-white; 69.9% had Medicare or Medicaid; 31.8% had coronary heart disease, 32.2% had heart failure, 13.0% had peripheral vascular disease, and 29.5% had diabetes mellitus. Among eligible patients, 62.8% of 3,612 were prescribed an antiplatelet agent, 72.1% of 4,674 were prescribed a β-blocker, 59.7% of 5,121 were prescribed an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, 15.7% of 624 were prescribed an aldosterone antagonist, 70.1% of 6,914 were prescribed a statin, 94.7% of 8,329 were prescribed an antihypertensive, 58.3% of 504 had an ICD, and 44.5% of 9,589 received all indicated evidence-based therapies ( Table ). Conclusion: Cardiovascular comorbidities and risk factors in patients with AF are often inadequately treated with evidence-based therapies in the outpatient practice setting, underscoring opportunities to improve care for patients with AF.
An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia
Peltenburg, Puck J. , Kallas, Dania , Bos, J. Martijn , Lieve, Krystien V.V. , Franciosi, Sonia , Roston, Thomas M. , Denjoy, Isabelle , Sorensen, Katrina B. , Ohno, Seiko , Rosés‐Noguer, Ferran , Aiba, Takeshi , Maltret, Alice , Atallah, Joseph , Giudicessi, John R. , Tanck, Michael W.T. , Kato, Koichi , Barc, Julien , Borggrefe, Martin, Behr, Elijah R. , Tfelt‐Hansen, Jacob , Zorio, Esther , Swan, Heikki, Kammeraad, Janneke A.E. , Sacher, Frédéric , Roberts, Jason D. , Berg, Maarten P. van den , Robyns, Tomas , Tavačová, Terézia , Semsarian, Christopher , Till, Jan , Horie, Minoru , Ackerman, Michael J. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Bos, Johan M , LaPage, Martin J , Atallah, Joseph , Giudicessi, J R , Clur, Sally-Ann B , Tanck, Michael , Extramiana, Fabrice , Kato, Koichi , Barc, Julien , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Zorio, Esther , Krahn, Andrew D , Davis, Andrew , Sacher, Frederic , Schwartz, Peter J. , Roberts, Jason D , Skinner, Jonathan R , van den Berg, Maarten P , Kannankeril, Prince J , Drago, Fabrizio , Robyns, Tomas , Haugaa, Kristina , Tavacova, Terezia , Semsarian, Christopher , Probst, Vincent , Brugada, Ramón , Shimizu, Wataru , Horie, Minoru , Leenhardt, Antoine , Ackerman, Michael J , Sanatani, Shubhayan , Wilde, Arthur A M , Denjoy, Isabelle , Rosés-Noguer, Ferran , Lieve, Krystien V , Peltenburg, Puck J , Ohno, Seiko , Aiba, Takeshi , Clur, Sally‐Ann B. , Blom, Nico A. , Sarquella-Brugada, Georgia , Krahn, Andrew D. , Davis, Andrew M. , Skinner, Jonathan R. , Kannankeril, Prince J. , Haugaa, Kristina H. , Leenhardt, Antoine , Werf, Christian van der

Mayo Clinic

Circulation | December 7, 2021 | Volume: 145 | Issue: 5 | Pages: 333-344

10.1161/circulationaha.121.056018 | PMID 34874747 Get It

Background: Symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for recurrent arrhythmic events. β-Blockers decrease this risk, but studies comparing individual β-blockers in sizeable cohorts are lacking. We aimed to assess the association between risk for arrhythmic events and type of β-blocker in a large cohort of symptomatic children with CPVT. Methods: From 2 international registries of patients with CPVT, RYR2 variant–carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and age at start of β-blocker therapy <18 years), treated with a β-blocker were included. Cox regression analyses with time-dependent covariates for β-blockers and potential confounders were used to assess the hazard ratio (HR). The primary outcome was the first occurrence of sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter-defibrillator shock, or syncope. The secondary outcome was the first occurrence of any of the primary outcomes except syncope. Results: We included 329 patients (median age at diagnosis, 12 [interquartile range, 7–15] years, 35% females). Ninety-nine (30.1%) patients experienced the primary outcome and 74 (22.5%) experienced the secondary outcome during a median follow-up of 6.7 (interquartile range, 2.8–12.5) years. Two-hundred sixteen patients (66.0%) used a nonselective β-blocker (predominantly nadolol [n=140] or propranolol [n=70]) and 111 (33.7%) used a β1-selective β-blocker (predominantly atenolol [n=51], metoprolol [n=33], or bisoprolol [n=19]) as initial β-blocker. Baseline characteristics did not differ. The HRs for both the primary and secondary outcomes were higher for β1-selective compared with nonselective β-blockers (HR, 2.04 [95% CI, 1.31–3.17]; and HR, 1.99 [95% CI, 1.20–3.30], respectively). When assessed separately, the HR for the primary outcome was higher for atenolol (HR, 2.68 [95% CI, 1.44–4.99]), bisoprolol (HR, 3.24 [95% CI, 1.47–7.18]), and metoprolol (HR, 2.18 [95% CI, 1.08–4.40]) compared with nadolol, but did not differ from propranolol. The HR of the secondary outcome was only higher in atenolol compared with nadolol (HR, 2.68 [95% CI, 1.30–5.55]). Conclusions: β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.
1198. Lyme Disease Post-Exposure Prophylaxis by Single-Dose Doxycycline in Three Healthcare Systems
Schotthoefer, Anna M. , Draper, Evan , Zeuli, John D. , Scotty, Erica, Pollak, Jonathan , Schwartz, Amy , Beck, Alyssa , Marx, Grace Ellen , Schwartz, Brian S. , Rivera, Christina G. , Hinckley, Alison F.

Mayo Clinic

Open Forum Infectious Diseases | December 5, 2021 | Volume: 8 | Issue: Supplement_1 | Pages: S690-S690

10.1093/ofid/ofab466.1390 Get It

Abstract Background Lyme disease, the most common tickborne disease in the United States, may be prevented by taking a single 200-mg dose of oral doxycycline after a high-risk bite from a blacklegged tick. Currently, it is not known how Lyme disease post-exposure prophylaxis (PEP) might vary by region and healthcare system. We identified single-dose doxycycline medication orders in three healthcare systems in states with high incidence of Lyme disease and compared associated patient and provider characteristics. Methods Electronic health record data during 2012 – 2016 were obtained from three healthcare systems: Geisinger (Pennsylvania), Marshfield Clinic (Wisconsin), and Mayo Clinic (Minnesota/Wisconsin). Creation of analytic variables and analysis were harmonized across the three sites. Medication orders for single-dose doxycycline ≤200 mg that were accompanied by specific key words or diagnostic codes (e.g., tick bite; Lyme disease prevention) were considered evidence of PEP. Manual chart review was performed from a random subset to evaluate the algorithms used to identify PEP. Results Among 2,937,585 patients with at least one medication order or clinical encounter during the study period, 14,102 single-dose doxycycline orders for Lyme disease PEP for 13,172 unique patients were identified. The typical patient receiving PEP was older (mean age 51 – 58 years), male (56 – 59%), and non-Hispanic White (81 – 98%). The annual seasonality of medication orders was bimodal, with peaks occurring during April – July and October – November. The most common encounter setting was an outpatient clinic or urgent care center (80 – 91%); medication orders after patient phone calls in the absence of an in-person visit occurred frequently (14 – 19%) in two health systems. Chart abstractions (n=600) revealed instances of PEP prescribed inappropriately (e.g., bite from a non-blacklegged tick; patient with symptoms of acute Lyme disease). Conclusion Lyme disease PEP with a single dose of doxycycline was frequently prescribed in healthcare systems where there is a high incidence of Lyme disease. PEP was most commonly prescribed to non-Hispanic Whites over the age of 50 years. Public health initiatives for tickborne disease prevention should include clinician education on the appropriate use of Lyme disease PEP. Disclosures Anna M. Schotthoefer, PhD, HelixBind (Other Financial or Material Support, salary support) John Zeuli, PharmD, INSMED (Other Financial or Material Support, honoraria for educational speaking)
A clinical primer for the glymphatic system
Carlstrom, Lucas P. , Eltanahy, Ahmed M. , Perry, Avital , Elder, Benjamin D. , Meyer, Fredric B. , Graffeo, Christopher S. , Lundgaard, Iben , Eltanahy, Ahmed, Rabinstein, Alejandro A. , Morris, Jonathan M. , Burns, Terry C.

Mayo Clinic

Brain | December 3, 2021 | Volume: 145 | Issue: 3 | Pages: 843-857

10.1093/brain/awab428 | PMID 34888633 Get It

Abstract The complex and dynamic system of fluid flow through the perivascular and interstitial spaces of the CNS has new-found implications for neurological diseases. CSF movement throughout the CNS parenchyma is more dynamic than could be explained via passive diffusion mechanisms alone. Indeed, a semistructured glial-lymphatic (glymphatic) system of astrocyte-supported extracellular perivascular channels serves to directionally channel extracellular fluid, clearing metabolites and peptides to optimize neurological function. Clinical studies of the glymphatic network have to date proven challenging, with most data gleaned from rodent models and post-mortem investigations. However, increasing evidence suggests that disordered glymphatic function contributes to the pathophysiology of CNS ageing, neurodegenerative disease and CNS injuries, as well as normal pressure hydrocephalus. Unlocking such pathophysiology could provide important avenues towards novel therapeutics. We here provide a multidisciplinary overview of glymphatics and critically review accumulating evidence regarding its structure, function and hypothesized relevance to neurological disease. We highlight emerging technologies of relevance to the longitudinal evaluation of glymphatic function in health and disease. Finally, we discuss the translational opportunities and challenges of studying glymphatic science.